Mechanism of cognitive function improvement in small vascular disease based on neural network reconstruction

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100055080

Enrollment

Unknown

Registered

2021-12-31

Start date

2021-01-01

Completion date

Unknown

Last updated

2023-01-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cerebral Small Vascular Disease (CSVD)

Interventions

cTBS group:cTBS stimulation

control group:routine rehabilitation

Eligibility

Sex/Gender

All

Age

40 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. MRI shows typical CSVD phenotype; 2. Meet the diagnostic criteria of ''Chinese Guidelines for Diagnosis and Treatment of Cerebral Small Vessel Disease-Related Cognitive Dysfunction (2019)''; 3. Primary school grade 6 or above; 4. There are stable and reliable caregivers, who will help patients to participate in the whole process of the study, and must have sufficient interaction and communication with the subjects in order to provide valuable information for the scale scoring; 5. Aged 40-80 years; 6. Willing to sign the informed consent.

Exclusion criteria

Exclusion criteria: 1. History of cerebral hemorrhage or subarachnoid hemorrhage; 2. Large artery atherosclerotic stroke; 3. Combined with other diseases that can lead to abnormal cognitive function, such as hypothyroidism, traumatic brain injury, congenital developmental delay and intracranial tumor; 4. Diagnosed with non-vascular dementia, such as Alzheimer's disease and Lewy body dementia; 5. Combined neurodegenerative diseases that can affect cognitive function, such as multiple sclerosis or Parkinson's disease; 6. There are visual or hearing impairments and cannot cooperate with the completion of the cognitive function assessment; 7. Patients with contraindications to TMS, such as intracranial implantation of metals, brain tumors, and patients with increased intracranial pressure.

Design outcomes

Primary

Measure	Time frame
Alzheimer's Disease Rating Scale - Cognitive Scale;Clearance efficiency of the glymphatic pathway;	—

Secondary

Measure	Time frame
Montreal Cognitive Assessment;Stroop Color Word Test;Trail Marking Test;Digital Span Test;	—

Countries

China

Contacts

Public ContactDai Pei

Beijing Tiantan Hospital, Capital Medical University

daipei1982@sina.com+86 13501289964

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026